Last reviewed · How we verify

LG Chem — Portfolio Competitive Intelligence Brief

LG Chem pipeline: 4 marketed, 0 filed, 1 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 1 Phase 3 8 Phase 2 19 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Dapagliflozin 10mg Dapagliflozin 10mg marketed
Guo Na Fen (Gonal-F) Guo Na Fen (Gonal-F) marketed Gonadotropin; recombinant FSH FSH receptor (FSHR) Reproductive Medicine / Fertility
Eupenta Inj. Eupenta Inj. marketed Antiprotozoal agent Parasite DNA and mitochondrial function Infectious Disease
Fang Le Shu (Follitrope) Fang Le Shu (Follitrope) marketed Gonadotropin; recombinant FSH FSH receptor (FSHR) Reproductive/Fertility
Eupolio Eupolio phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
  2. Fertility Biotech AG · 1 shared drug class
  3. IVFarma LLC · 1 shared drug class
  4. Merck KGaA, Darmstadt, Germany · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for LG Chem:

Cite this brief

Drug Landscape (2026). LG Chem — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lg-chem. Accessed 2026-06-10.

Related